全球肢体解剖分期系统与慢性肢体威胁性缺血腹股沟下血运重建结局相关
本研究回顾性分析167例患者194条肢体的慢性肢体威胁性缺血(CLTI)病例,评估全球肢体解剖分期系统(GLASS)与血运重建结局的关系。结果显示GLASS 3与腹股沟下血运重建后主要不良肢体事件无生存率降低独立相关(HR 2.35),且与总体生存率、无截肢生存率和无再干预生存率降低相关。
要点
- GLASS 3与血运重建后主要不良肢体事件风险独立相关(HR 2.35)。
- GLASS 3患者腔内治疗的技术失败率更高(22%)。
- GLASS分期有助于CLTI血运重建的临床决策。
核心结论
- GLASS 3与CLTI患者血运重建后主要不良临床结局强烈相关。
研究设计与样本
- 回顾性队列研究,纳入2017年1月至2019年7月在一家三级转诊中心因静息痛或组织缺损行外周血管造影的连续患者。
- 共纳入167例患者194条肢体,排除严重主髂动脉病变、既往腹股沟下支架或功能旁路移植及GLASS 0者。
- GLASS评分基于介入前血管造影,由治疗医生确定 primary infrapopliteal target artery pathway。
主要发现
- 194条肢体中90%(175/194)表现为组织缺损,83%(149/182)为WIfI 3或4期。
- GLASS分期分布:GLASS 1占14%,GLASS 2占18%,GLASS 3占68%。
- 52条旁路手术肢体中85%为GLASS 3,108条腔内治疗(EVI)肢体中55%为GLASS 3(P < .001)。
- 34条肢体未行血运重建,其中85%为GLASS 3。
- EVI即刻技术失败(未能建立目标动脉通路)仅见于GLASS 3解剖(n = 13;22%)。
关键数值与推荐
- 中位随访10个月,EVI后肢体基于通畅率GLASS 3显著低于GLASS 1或2(42% vs 59%;P = .018)。
- GLASS 3与EVI组(P = .002)及整体血运重建队列(P = .001)主要不良肢体事件无生存率降低相关。
- GLASS 3亦与总体生存率、无截肢生存率和无再干预生存率显著降低相关。
- Cox比例风险模型中,GLASS 3(HR 2.35;95%CI 1.30-4.24;P = .005)和WIfI伤口分级3(HR 2.64;95%CI 1.26-5.53;P = .010)是血运重建后主要不良肢体事件无生存率降低的独立预测因素。
临床怎么用
- GLASS 3期CLTI患者血运重建后结局较差,应加强围手术期管理和随访。
- 对于GLASS 3解剖,EVI技术失败风险较高,需谨慎选择血运重建方式。
局限性
- 回顾性单中心研究,样本量有限。
- 中位随访时间仅10个月,长期结局未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Global Limb Anatomic Staging System (GLASS) has been proposed to facilitate clinical decision-making regarding revascularization for chronic limb threatening ischemia (CLTI). The purpose of the present study was to define its relationship to the treatment outcomes in CLTI. METHODS: Consecutive patients who had undergone peripheral angiography for rest pain or tissue loss from January 2017 to July 2019 at a tertiary referral center with a dedicated limb preservation program were reviewed. Subjects with significant aortoiliac disease, previous infrainguinal stenting or functioning bypass grafts, or GLASS stage 0 were excluded. The GLASS score was assigned from the preintervention angiography findings, and the treating surgeon determined the primary infrapopliteal target artery pathway for the limb at risk. The demographic data, procedural details, and clinical outcomes were analyzed. RESULTS: The study cohort included 167 patients and 194 limbs, of which 175 of 194 limbs (90%) had presented with tissue loss and 149 of 182 limbs (83%) with WIfI (Wound, Ischemia and foot Infection) stage 3 or 4. The GLASS stage was GLASS 1 in 14%, GLASS 2 in 18%, and GLASS 3 in 68%. GLASS 3 anatomy was present in 85% of 52 limbs treated by bypass and 55% of 108 limbs treated by endovascular intervention (EVI; P < .001). Revascularization was not performed in 34 limbs, most of which were GLASS 3 (85%). Immediate technical failure for EVI (ie, failure to establish target artery pathway) occurred exclusively in the setting of GLASS 3 anatomy (n = 13; 22%). After a median follow-up of 10 months, limb-based patency after EVI was significantly lower in GLASS 3 than in GLASS 1 or 2 limbs (42% vs 59%; P = .018). GLASS 3 was associated with reduced major adverse limb events-free survival in both the EVI group (P = .002) and the overall revascularized cohort (P = .001). GLASS 3 was also associated with significantly reduced overall survival, amputation-free survival, and reintervention-free survival. In a Cox proportional hazards model, GLASS 3 (hazard ratio, 2.35; 95% confidence interval, 1.30-4.24; P = .005) and WIfI wound grade 3 (hazard ratio, 2.64; 95% confidence interval, 1.26-5.53; P = .010) were independent predictors of reduced major adverse limb events-free survival after revascularization. CONCLUSIONS: GLASS stage 3 was strongly associated with major adverse clinical outcomes after revascularization in patients with CLTI.
引用
- El Khoury R, Wu B, Edwards CT, et al. The Global Limb Anatomic Staging System is associated with outcomes of infrainguinal revascularization in chronic limb threatening ischemia. J Vasc Surg. 2021. PMID: 33548444. doi:10.1016/j.jvs.2020.12.094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。